BioWorld

May 9, 2002

Amgen Paying Roche $137.5M For European Neupogen Rights

Amgen Inc. said it will pay Roche Holding AG $137.5 million to gain control over European assets and business related to two white-cell boosters that are sold in the U.S. under the names Neupogen and Neulasta. (BioWorld Today) Read More

GenStar, Applied Molecular Sign Collaborations With Centocor

Striatal Genes, Proteins Couple, Uncouple As Mutant Huntingtin Gene Interferes With Brain Cells

Affinium, Pfizer Enter Potential $30M Drug Discovery Alliance

Other News To Note

Immusol, Vertex Collaborating To Discover Protein Targets

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Aug. 13, 2025.

Bayer secures KRAS G12D inhibitor with $1.3B Kumquat deal

BioWorld

With a packed pipeline of drug candidates targeting multiple markers of cancer, Bayer AG signed on for a new project, this time going after the KRAS pathway with...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for August 13, 2025.

Microscopic image of blood cells, chronic myeloid leukemia and thrombocytosis

Scemblix ticks Novartis earnings box; more ahead in CML

BioWorld

Novartis AG’s financial update included good news about Scemblix (asciminib), the first and only U.S. FDA-approved allosteric inhibitor for chronic myeloid...

NME Digest: Q2 2025

BioWorld

A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...